| 2026-08-21 16:31 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Nuvectis established ATM offering program; routine capital raise with no M&A implications. |
SEC · detail |
| 2026-08-04 08:25 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q2 2026 earnings report with no M&A indicators, activist involvement, or strategic transaction language. |
SEC · detail |
| 2026-06-30 16:43 |
8-K |
["1.01", "8.01", "9.01"] |
other |
0.05
|
Public equity offering by Nuvectis; no M&A signals present. |
SEC · detail |
| 2026-06-29 16:07 |
8-K |
["8.01"] |
other |
0.05
|
Routine 8-K disclosing suspension of at-the-market offering; no M&A signals. |
SEC · detail |
| 2026-06-23 07:00 |
8-K |
["1.01", "8.01", "9.01"] |
material agreement |
0.15
|
License agreement with Haisco for two drug programs; M&A-relevant change-of-control clause but no acquisition signal. |
SEC · detail |
| 2026-06-12 16:05 |
8-K |
["5.07"] |
other |
0.00
|
Routine 8-K filing of 2026 Annual Meeting voting results; no M&A signals. |
SEC · detail |
| 2026-05-05 07:36 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings disclosure with no M&A-related content or language. |
SEC · detail |